FDA rejects Capricor Therapeutics Duchenne muscular dystrophy cell therapy
The United States regulator has refused approval for deramiocel after trials failed to show the cell therapy slowed heart failure or muscle loss.
FTMQ Health, written by our newsroom0 views

The United States Food and Drug Administration rejected a cell therapy developed by Capricor Therapeutics for Duchenne muscular dystrophy on Friday, STAT News reported. The drug, called deramiocel, was intended to treat teenagers and young men who have lost the ability to walk. [1][3]
Capricor conducted two randomized clinical trials to test the treatment. According to STAT News, both trials failed to demonstrate that deramiocel could prevent heart failure or preserve muscle function in participants. [1]
Duchenne muscular dystrophy is a severe genetic disorder, and patients who can no longer walk currently have few treatment options. STAT News reported that the regulator blocked the drug from reaching the market because it did not help patients in the trials. [1]
Under the 21st Century Cures Act, the Food and Drug Administration can grant Regenerative Medicine Advanced Therapy status to candidate drugs. That designation allows drug developers to seek accelerated approval based on intermediate clinical endpoints. [4]
In short
- The FDA rejected Capricor Therapeutics cell therapy deramiocel on Friday.
- Deramiocel was aimed at treating teenagers and young men with Duchenne muscular dystrophy who cannot walk.
- Two randomized clinical trials failed to show the therapy preserved muscle function or prevented heart failure.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time comingSTAT News, 15h ago (the report this story comes from)
- [2]FDA rejects Capricor Therapeutics' Duchenne therapy, a decision that was a long time comingSTAT, 15h ago
- [3]FDA rejects Capricor’s deramiocel cell therapy — STAT NewsUA.NEWS, 15h ago
Background
- [4]Regenerative medicine advanced therapy on Wikipedia
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Servier muscular dystrophy drug fails trialTop Stories, 17d ago
- Former Eli Lilly representative sues over Mounjaro marketing complaintsTop Stories, 10d ago
- United Therapeutics performs first UThymoKidney transplant in EXTEND trialTop Stories, 15h ago
- CAR T cell therapy analysis reveals high inflammation but low mortalityMedical Science, 3d ago
- Heart failure deaths double among younger and middle aged AmericansTop Stories, 44d ago
More in Top Stories
- United Therapeutics performs first UThymoKidney transplant in EXTEND trial15h ago
- Princeton neuroscience researcher detained by ICE following conference15h ago
- Northern Ireland ambulance service misses two-hour target over 2,000 times1d ago
- Senior surgeon calls for police investigation into Scottish hospital patient deaths1d ago
- Malaria antibody prevents infection in infants but interferes with vaccine1d ago
- Seasonal mass vaccination with R21 vaccine cuts malaria infection risk1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.